NICE says no to expensive kidney cancer drugs

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

The advisory committee tothe UK’s National Health Service(NHS) has recommended that theNHS not pay for four new agentsproven effective in metastatic renalcell carcinoma. The four drugs arebevacizumab (Avastin), sorafenib(Nexavar), sunitinib (Sutent), andtemsirolimus (Torisel).

The advisory committee to the UK’s National Health Service (NHS) has recommended that the NHS not pay for four new agents proven effective in metastatic renal cell carcinoma. The four drugs are bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), and temsirolimus (Torisel).

In a written statement, the National Institute for Health and Clinical Excellence (NICE) stressed that their vote against the four agents is a preliminary one; the final guidance to the NHS will be rendered later this month and after public input.

Professor Peter Littlejohns, clinical and public health director for NICE, explained that “bevacizumab, sorafenib, sunitinib, or temsirolimus have the potential to extend progression-free survival (in renal cancer patients), but at a cost of £20,000- £35,000 per patient per year...although these treatments are clinically effective, they are not a cost-effective use of NHS resources.”

However, Professor Littlejohns said that NICE would consider proposals from the drugs manufacturers- Bayer/Onyx, Pfizer, Roche, and Wyeth-for reducing the cost of the drugs. To read the draft guidance, go to: http:// www.nice.org.uk/guidance/index. jsp?action=byID&o=11817

In an interview with a UK newspaper, Sir Michael Rawlins, NICE chairman, accused drug companies of driving up the price of medicines. Professor Rawlins said that pharmaceutical companies are too focused on maintaining profits, supporting marketing, and cushioning themselves against competition when patents expire (BBC News, August 17, 2008).

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content